Navigation Links
Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
Date:9/8/2009

DURHAM, N.C., Sept. 8 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced that it has formally notified Vatea Fund of the company's achievement of a milestone under the Securities Purchase Agreement dated June 8, 2009, as amended September 1, 2009. The milestone is a Clinical Trial for Oxycyte in Traumatic Brain Injury Approved by Swissmedic.

With the achievement of the milestone, the agreement calls for Vatea Fund to purchase 24 million shares of Oxygen Biotherapeutics stock from the company for $6 million with the transaction to close no later than December 10, 2009.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at www.oxybiomed.com.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
2. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
3. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
4. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
5. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
6. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... N.J. , Feb. 8, 2016  Otsuka Pharmaceutical ... announced that they have entered into a licensing agreement ... in the U.S. and Puerto Rico ... a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a new ... --> In a Phase II clinical ...
(Date:2/8/2016)... LAWRENCEVILLE, N.J. , Feb. 8, 2016   ... for healthcare professionals to guide them through GS1 Standards ... and Drug Administration (FDA) Unique Device Identification (UDI) rule. ... standards, GS1 US; Beth Gibson , senior director ... Roberts , industry development director, GS1 US ...
(Date:2/8/2016)... MEMPHIS, Tenn. , Feb. 8, 2016  A ... Hospital scientists has discovered details of how the ... cells triggers a particularly aggressive form of acute lymphoblastic ... cells, in which genetic mutations trigger overproduction of immature ... --> The discoveries of the malfunction underlying the ...
Breaking Medicine Technology:
(Date:2/8/2016)... Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... and surrounding areas with a vital new community enrichment program, has teamed up with ... local women and children suffering from intimate abuse. To support all those victimized by ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted February 8, 2016 ... Awards. , Awards include the Information Security Executive® of the Year, ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show ... to see the most incredible gardens and home improvement experts that attend this amazing ... Center - 700 14th St. Denver CO, is an exciting event that Performance Mobility ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... with the latest techniques and the most minimally invasive approaches. , Women who ... particularly after menopause. Other risk factors include surgery to the pelvic floor, connective ...
Breaking Medicine News(10 mins):